Supreme Court Preserves Telehealth, Mail Access To Mifepristone
High court granted a stay preserving telehealth prescriptions and mail delivery of mifepristone while Louisiana v. FDA and FDA review proceed.
The InterceptA “Scheme” Against Dobbs: SCOTUS Dissent Hints at Next Phase of Abortion Rights Fight
World News GroupAs courts deliberate, abortions continue arriving by mail
The NationWhat the Dissents in the Mifepristone Case Tell Us About What’s to Come
SlateSamuel Alito Is Fuming That Blue States Outsmarted His Dobbs Decision
Overview
The Supreme Court on Thursday granted a stay that preserves telehealth prescriptions and mail delivery of mifepristone while litigation in Louisiana v. FDA proceeds.
The move followed a May 1 order by the 5th U.S. Circuit Court of Appeals that briefly reinstated a pre-2021 in-person dispensing requirement and litigation tracing to FDA policy changes in 2021 and 2023.
Justices Clarence Thomas and Samuel Alito dissented, with Thomas citing the Comstock Act and Alito calling the policy a "scheme" to evade Dobbs, their dissenting opinions said.
Medication abortions were roughly two-thirds of U.S. abortions in 2023, more than one in four abortions use telehealth today, and mailed shipments rose from about 74,000 in 2024 to 91,000 last year, Guttmacher reported.
The 5th U.S. Circuit will weigh the merits next, the case may return to the Supreme Court, and FDA review and potential enforcement decisions could further affect access.
Analysis
Center-leaning sources frame the coverage skeptically toward political theater and foreground legal and procedural stakes. Editorial word choices ("announcing approximately zero results," "buzzword-speak") and selective emphasis on official statements and court dissents steer reader interpretation, while direct quotes remain source content and illustrate competing viewpoints.